Softwall Equipment Corp. Inc. Agrees to Acquire Inncardio Inc.

Softwall Equipment Corp. Inc. Agrees to Acquire Inncardio Inc.



SALT LAKE CITY, Feb. 18  /PRNewswire-FirstCall/ -- Softwall Equipment Corp.
(OTC:SWLE) (BULLETIN BOARD: SWLE)  has today announced that it has agreed to
acquire Inncardio Inc., a Delaware corporation engaged in the business of
acquiring developing and commercializing pharmaceutical products targeted at
various Cardiovascular diseases.  Under the terms of the agreement closing will
take place on Tuesday 22nd February 2005.

Upon consummation of the transaction, there will be a change in control of
Softwall and the Officers, Directors and shareholders of Inncardio Inc. shall
assume control of Softwall Equipment Corp.  Softwall Equipment Corp. shall then
change its name to Inncardio Inc.

Inncardio Inc. is currently a wholly owned subsidiary of Bioaccelerate Holdings
Inc. (OTC:BACL) (BULLETIN BOARD: BACL) , a company that acquires and invests in
the development of pharmaceutical compounds.

About Inncardio, Inc.

Inncardio Inc. is a biotechnology company engaged in the acquisition,
development and commercialization of treatments and therapies targeted at
various cardiovascular diseases.  Inncardio currently has 6 products in its
portfolio, 3 of them in clinical development and 3 in pre-clinical development
which address significant commercial opportunities.  The compounds under
development have the potential of becoming blockbuster drugs in their
respective markets if approved.  The management of Inncardio are focused on the
ongoing development of Inncardio's products to build value prior to partnering
and seek the In-licensing of additional identified cardiovascular products to
further enhance commercial value.  Many top cardiovascular players are
vulnerable to key patent expiries over the next 6 years will need to fill
pipelines from external sources and preference will be given to products with
clinical validation.

About Bioaccelerate Holdings Inc.

Bioaccelerate Holdings Inc. is a pharmaceutical development organization that
seeks to acquire, develop and commercialize novel pharmaceutical compounds in
an efficient, cost-effective way for the benefit patients and its shareholders.
 Bioaccelerate uses its broad network of academic, industry and capital market
relationships to expedite drug development and raise capital to create and fund
its subsidiary companies, which are organized by vertical portfolios in five
therapeutic areas: oncology, specialty pharmaceuticals, central nervous system
disorders (CNS), cardiovascular disease and anti-infectives.

Bioaccelerate conducts its business directly and through its subsidiaries. The
company holds majority equity interests in ten biopharmaceutical companies
(three of which are public) and holds minority interests in four
biopharmaceutical companies (two of which are public).  The company also holds
a minority equity interest in a public nanotechnology company.

Bioaccelerate's strategy relies on its development network for research,
clinical development and project management to guide early-stage compounds from
the discovery process through to Phase II/III development where incremental
value can be created.  Bioaccelerate Holdings is quoted on the Over-The-Counter
Bulletin Board under the symbol "BACL.OB."  For more information on
Bioaccelerate, visit the company's website at http://www.bioaccelerate.com/.

Safe Harbour Statement

Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements.  Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements
include, but are not limited to: risks associated with pre-clinical and
clinical developments in the biopharmaceutical industry in general and in
compounds under development in particular; the potential failure of compounds
under development to prove safe and effective for treatment of disease;
uncertainties inherent in the early stage of the Company's compounds under
development; failure to successfully implement or complete clinical trials;
failure to receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change the company's business, structure or
projections; the development of competing products; uncertainties related to
the company's dependence on third parties and partners.  The Company disclaims
any obligation to update these forward-looking statements. 

DATASOURCE: Softwall Equipment Corp. Inc.



CONTACT:  Softwall Equipment Corp. Inc., [phone]



Web site:  http://www.bioaccelerate.com/ 

Copyright